Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
UTHR Quote, Financials, Valuation and Earnings
Last price:
$514.01
Seasonality move
:
5.61%
Day range:
$509.12 - $519.99
52-week range:
$266.98 - $519.99
Dividend yield:
0%
P/E ratio:
19.35x
P/S ratio:
7.87x
P/B ratio:
3.33x
Volume:
382.8K
Avg. volume:
481.8K
1-year change:
40.37%
Market cap:
$22B
Revenue:
$2.9B
EPS (TTM):
$26.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$812.9M | $7.31 | 11.02% | 17.13% | $518.25 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.54% | 310.03% | $325.88 |
|
CORT
Corcept Therapeutics, Inc.
|
$218.5M | $0.14 | 43.56% | 32.34% | $127.20 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.49% | 33.42% | $132.38 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
JNJ
Johnson & Johnson
|
$23.8B | $2.76 | 7.18% | 79.14% | $209.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$510.44 | $518.25 | $22B | 19.35x | $0.00 | 0% | 7.87x |
|
AMGN
Amgen, Inc.
|
$331.35 | $325.88 | $178.4B | 25.62x | $2.38 | 2.87% | 5.00x |
|
CORT
Corcept Therapeutics, Inc.
|
$81.99 | $127.20 | $8.6B | 93.68x | $0.00 | 0% | 13.22x |
|
GILD
Gilead Sciences, Inc.
|
$125.19 | $132.38 | $155.3B | 19.39x | $0.79 | 2.52% | 5.42x |
|
INSM
Insmed, Inc.
|
$176.77 | $214.78 | $37.7B | -- | $0.00 | 0% | 75.23x |
|
JNJ
Johnson & Johnson
|
$205.78 | $209.29 | $495.8B | 19.86x | $1.30 | 2.5% | 5.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
-- | 1.213 | -- | 5.61x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.063 | 0.07% | 2.85x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$698.6M | $389.3M | 18.69% | 19.2% | 48.69% | $346.1M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
United Therapeutics Corp. vs. Competitors
-
Which has Higher Returns UTHR or AMGN?
Amgen, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 33.55%. United Therapeutics Corp.'s return on equity of 19.2% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About UTHR or AMGN?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 1.53%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -1.66%. Given that United Therapeutics Corp. has higher upside potential than Amgen, Inc., analysts believe United Therapeutics Corp. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 AMGNAmgen, Inc.10 15 2 -
Is UTHR or AMGN More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock UTHR or AMGN?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.87% to investors and pays a quarterly dividend of $2.38 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or AMGN?
United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. United Therapeutics Corp.'s net income of $338.7M is lower than Amgen, Inc.'s net income of $3.2B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.35x while Amgen, Inc.'s PE ratio is 25.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.87x versus 5.00x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.87x 19.35x $799.5M $338.7M AMGNAmgen, Inc.5.00x 25.62x $9.6B $3.2B
-
Which has Higher Returns UTHR or CORT?
Corcept Therapeutics, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 9.32%. United Therapeutics Corp.'s return on equity of 19.2% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About UTHR or CORT?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 1.53%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $127.20 which suggests that it could grow by 55.14%. Given that Corcept Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 CORTCorcept Therapeutics, Inc.3 2 0 -
Is UTHR or CORT More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.287%.
-
Which is a Better Dividend Stock UTHR or CORT?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or CORT?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. United Therapeutics Corp.'s net income of $338.7M is higher than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.35x while Corcept Therapeutics, Inc.'s PE ratio is 93.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.87x versus 13.22x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.87x 19.35x $799.5M $338.7M CORTCorcept Therapeutics, Inc.13.22x 93.68x $207.6M $19.4M
-
Which has Higher Returns UTHR or GILD?
Gilead Sciences, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 39.21%. United Therapeutics Corp.'s return on equity of 19.2% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About UTHR or GILD?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 1.53%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.74%. Given that Gilead Sciences, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Gilead Sciences, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 GILDGilead Sciences, Inc.16 8 0 -
Is UTHR or GILD More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock UTHR or GILD?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or GILD?
United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. United Therapeutics Corp.'s net income of $338.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.35x while Gilead Sciences, Inc.'s PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.87x versus 5.42x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.87x 19.35x $799.5M $338.7M GILDGilead Sciences, Inc.5.42x 19.39x $7.8B $3.1B
-
Which has Higher Returns UTHR or INSM?
Insmed, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -259.95%. United Therapeutics Corp.'s return on equity of 19.2% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About UTHR or INSM?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 1.53%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 21.6%. Given that Insmed, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Insmed, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 INSMInsmed, Inc.17 1 0 -
Is UTHR or INSM More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock UTHR or INSM?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or INSM?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. United Therapeutics Corp.'s net income of $338.7M is higher than Insmed, Inc.'s net income of -$370M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.35x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.87x versus 75.23x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.87x 19.35x $799.5M $338.7M INSMInsmed, Inc.75.23x -- $142.3M -$370M
-
Which has Higher Returns UTHR or JNJ?
Johnson & Johnson has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 21.47%. United Therapeutics Corp.'s return on equity of 19.2% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About UTHR or JNJ?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 1.53%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.71%. Given that Johnson & Johnson has higher upside potential than United Therapeutics Corp., analysts believe Johnson & Johnson is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 JNJJohnson & Johnson9 11 0 -
Is UTHR or JNJ More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
-
Which is a Better Dividend Stock UTHR or JNJ?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTHR or JNJ?
United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Johnson & Johnson quarterly revenues of $24B. United Therapeutics Corp.'s net income of $338.7M is lower than Johnson & Johnson's net income of $5.2B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 19.35x while Johnson & Johnson's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.87x versus 5.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.87x 19.35x $799.5M $338.7M JNJJohnson & Johnson5.41x 19.86x $24B $5.2B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
